ArticleScientific reports2017
Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 75 citations in OpenAlex.
- PEGylation Enhances Colloidal Stability and Promotes Ligand-Mediated Targeting of LAF-Xenopeptide mRNA Complexes.Polymers · 2025Article
- Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level.Nature biomedical engineering · 2025Review
- Current clinical applications of RNA-LNPs in regenerative medicine.Regenerative medicine · 2025Article
- Review
- Advances in Natural-Product-Based Fluorescent Agents and Synthetic Analogues for Analytical and Biomedical Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.Journal of nanobiotechnology · 2024Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Nanoconstructs for theranostic application in cancer: Challenges and strategies to enhance the delivery.Frontiers in pharmacology · 2023Review
- Broad-Spectrum Theranostics and Biomedical Application of Functionalized Nanomaterials.Polymers · 2022Review
- Targeted design of green carbon dot-CA-125 aptamer conjugate for the fluorescence imaging of ovarian cancer cell.Cell biochemistry and biophysics · 2022Article
- Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.Chemical biology & drug design · 2022Article
- Review
- Nanocarriers for delivery of siRNA as gene silencing mediator.EXCLI journal · 2022Review
- Smart Stimuli-Responsive Liposomal Nanohybrid Systems: A Critical Review of Theranostic Behavior in Cancer.Pharmaceutics · 2021Review
- Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides.Beilstein journal of organic chemistry · 2021Article
- Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery.Molecules (Basel, Switzerland) · 2020Review
- Lipid-oligonucleotide conjugates for bioapplications.National science review · 2020Article
- Non-cationic Material Design for Nucleic Acid Delivery.Advanced therapeutics · 2020Article
- Aptamer-guided extracellular vesicle theranostics in oncology.Theranostics · 2020Review
- Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.Pharmaceutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-application of fluorescent quantum dot nanocrystals and therapeutics has recently become a promising theranostic methodology for cancer treatment. We developed a tumor-targeted lipid nanocarrier that demonstrates notable efficacy in gene delivery as well as tumor bio-imaging. Coupling of aptamer molecules against the EGF receptor (EGFR) to the distal termini of lipid nanoparticles provided the carrier with tumor-specific recognition capability. The cationic lipid component, referred to as O,O'-dimyristyl-N-lysyl glutamate (DMKE), was able to effectively complex with anionic small-interfering RNA (siRNA). The hydrophobic quantum dots (Q-dots) were effectively incorporated in hydrophobic lipid bilayers at an appropriate Q-dot to lipid ratio. In this study, we optimized the liposomal formula of aptamer-conjugated liposomes containing Q-dots and siRNA molecules (Apt-QLs). The anti-EGFR Apt-QLs exhibited remarkable EGFR-dependent siRNA delivery as well as fluorescence imaging, which were analyzed in cultured cancer cells and tumor xenografts in mice. These results imply that the formulation of Apt-QLs could be widely utilized as a carrier for tumor-directed gene delivery and bio-imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.